RATIONALE: While neurosteroids are well-described positive allosteric modulators of gamma-aminobutyric acid type A (GABAA) receptors, the binding sites that mediate these actions have not been definitively identified. OBJECTIVES: This study was conducted to synthesize neurosteroid analogue photolabeling reagents that closely mimic the biological effects of endogenous neurosteroids and have photochemical properties that will facilitate their use as tools for identifying the binding sites for neurosteroids on GABAA receptors. RESULTS: Two neurosteroid analogues containing a trifluromethyl-phenyldiazirine group linked to the steroid C11 position were synthesized. These reagents, CW12 and CW14, are analogues of allopregnanolone (5α-reduced steroid) and pregnanolone (5β-reduced steroid), respectively. Both reagents were shown to have favorable photochemical properties with efficient insertion into the C-H bonds of cyclohexane. They also effectively replicated the actions of allopregnanolone and pregnanolone on GABAA receptor functions: they potentiated GABA-induced currents in Xenopus laevis oocytes transfected with α1β2γ2L subunits, modulated [(35)S]t-butylbicyclophosphorothionate binding in rat brain membranes, and were effective anesthetics in Xenopus tadpoles. Studies using [(3)H]CW12 and [(3)H]CW14 showed that these reagents covalently label GABAA receptors in both rat brain membranes and in a transformed human embryonal kidney (TSA) cells expressing either α1 and β2 subunits or β3 subunits of the GABAA receptor. Photolabeling of rat brain GABAA receptors was shown to be both concentration-dependent and stereospecific. CONCLUSIONS: CW12 and CW14 have the appropriate photochemical and pharmacological properties for use as photolabeling reagents to identify specific neurosteroid-binding sites on GABAA receptors.
RATIONALE: While neurosteroids are well-described positive allosteric modulators of gamma-aminobutyric acid type A (GABAA) receptors, the binding sites that mediate these actions have not been definitively identified. OBJECTIVES: This study was conducted to synthesize neurosteroid analogue photolabeling reagents that closely mimic the biological effects of endogenous neurosteroids and have photochemical properties that will facilitate their use as tools for identifying the binding sites for neurosteroids on GABAA receptors. RESULTS: Two neurosteroid analogues containing a trifluromethyl-phenyldiazirine group linked to the steroid C11 position were synthesized. These reagents, CW12 and CW14, are analogues of allopregnanolone (5α-reducedsteroid) and pregnanolone (5β-reducedsteroid), respectively. Both reagents were shown to have favorable photochemical properties with efficient insertion into the C-H bonds of cyclohexane. They also effectively replicated the actions of allopregnanolone and pregnanolone on GABAA receptor functions: they potentiated GABA-induced currents in Xenopus laevis oocytes transfected with α1β2γ2L subunits, modulated [(35)S]t-butylbicyclophosphorothionate binding in rat brain membranes, and were effective anesthetics in Xenopus tadpoles. Studies using [(3)H]CW12 and [(3)H]CW14 showed that these reagents covalently label GABAA receptors in both rat brain membranes and in a transformed humanembryonal kidney (TSA) cells expressing either α1 and β2 subunits or β3 subunits of the GABAA receptor. Photolabeling of rat brain GABAA receptors was shown to be both concentration-dependent and stereospecific. CONCLUSIONS:CW12 and CW14 have the appropriate photochemical and pharmacological properties for use as photolabeling reagents to identify specific neurosteroid-binding sites on GABAA receptors.
Authors: D F Covey; D Nathan; M Kalkbrenner; K R Nilsson; Y Hu; C F Zorumski; A S Evers Journal: J Pharmacol Exp Ther Date: 2000-06 Impact factor: 4.030
Authors: Alex S Evers; Zi-Wei Chen; Brad D Manion; Mingcheng Han; Xin Jiang; Ramin Darbandi-Tonkabon; Tristan Kable; John Bracamontes; Charles F Zorumski; Steven Mennerick; Joe Henry Steinbach; Douglas F Covey Journal: J Pharmacol Exp Ther Date: 2010-02-02 Impact factor: 4.030
Authors: Ramin Darbandi-Tonkabon; Brad D Manion; William R Hastings; William J Craigen; Gustav Akk; John R Bracamontes; Yejun He; Tatiana V Sheiko; Joseph H Steinbach; Steven J Mennerick; Douglas F Covey; Alex S Evers Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030
Authors: Mariangela Chisari; Lawrence N Eisenman; Kathiresan Krishnan; Achintya K Bandyopadhyaya; Cunde Wang; Amanda Taylor; Ann Benz; Douglas F Covey; Charles F Zorumski; Steven Mennerick Journal: J Neurophysiol Date: 2009-06-24 Impact factor: 2.714
Authors: Ping Li; John Bracamontes; Bryson W Katona; Douglas F Covey; Joe Henry Steinbach; Gustav Akk Journal: Mol Pharmacol Date: 2007-03-06 Impact factor: 4.436
Authors: Pavel Y Savechenkov; David C Chiara; Rooma Desai; Alexander T Stern; Xiaojuan Zhou; Alexis M Ziemba; Andrea L Szabo; Yinghui Zhang; Jonathan B Cohen; Stuart A Forman; Keith W Miller; Karol S Bruzik Journal: Eur J Med Chem Date: 2017-04-21 Impact factor: 6.514
Authors: Wayland W L Cheng; Zi-Wei Chen; John R Bracamontes; Melissa M Budelier; Kathiresan Krishnan; Daniel J Shin; Cunde Wang; Xin Jiang; Douglas F Covey; Gustav Akk; Alex S Evers Journal: J Biol Chem Date: 2018-01-04 Impact factor: 5.157
Authors: Harriet Hammer; Benjamin M Bader; Corina Ehnert; Christoffer Bundgaard; Lennart Bunch; Kirsten Hoestgaard-Jensen; Olaf H-U Schroeder; Jesper F Bastlund; Alexandra Gramowski-Voß; Anders A Jensen Journal: Mol Pharmacol Date: 2015-06-08 Impact factor: 4.436
Authors: Zi-Wei Chen; John R Bracamontes; Melissa M Budelier; Allison L Germann; Daniel J Shin; Krishnan Kathiresan; Ming-Xing Qian; Brad Manion; Wayland W L Cheng; David E Reichert; Gustav Akk; Douglas F Covey; Alex S Evers Journal: PLoS Biol Date: 2019-03-07 Impact factor: 8.029